These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 27440191)

  • 1. Combination of cisplatin and lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma: Report of two cases.
    Metaxas Y; Cathomas R; Mark M; von Moos R
    Lung Cancer; 2016 Dec; 102():136-138. PubMed ID: 27440191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).
    Metaxas Y; Früh M; Eboulet EI; Grosso F; Pless M; Zucali PA; Ceresoli GL; Mark M; Schneider M; Maconi A; Perrino M; Biaggi-Rudolf C; Froesch P; Schmid S; Waibel C; Appenzeller C; Rauch D; von Moos R;
    Ann Oncol; 2020 Apr; 31(4):495-500. PubMed ID: 32085891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival of mesothelioma in a palliative medical care unit in egypt.
    Ibrahim N; Abou-Elela E; Darwish D
    Asian Pac J Cancer Prev; 2013; 14(2):739-42. PubMed ID: 23621229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction chemotherapy vs post-operative adjuvant therapy for malignant pleural mesothelioma.
    Marulli G; Faccioli E; Bellini A; Mammana M; Rea F
    Expert Rev Respir Med; 2017 Aug; 11(8):649-660. PubMed ID: 28580813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anti-tumor immunotherapy in malignant pleural mesothelioma].
    Scherpereel A; Willemin MC; Wasielewski E; Dhalluin X
    Rev Mal Respir; 2018 Apr; 35(4):465-476. PubMed ID: 29415822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
    Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
    Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics, treatment and survival outcomes in malignant pleural mesothelioma: an institutional experience in Turkey.
    Kucukoner M; Ali Kaplan M; Inal A; Urakci Z; Abakay O; Cetin Tanrikulu A; Abakay A; Selim Sen H; Turkcu G; Senyigit A; Buyukbayram H; Isikdogan A
    J BUON; 2014; 19(1):164-70. PubMed ID: 24659659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
    Nowak AK; Lesterhuis WJ; Kok PS; Brown C; Hughes BG; Karikios DJ; John T; Kao SC; Leslie C; Cook AM; Pavlakis N; Briscoe K; O'Byrne KJ; Karapetis CS; Lam WS; Langford A; Yip S; Stockler MR
    Lancet Oncol; 2020 Sep; 21(9):1213-1223. PubMed ID: 32888453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The timing of chemotherapy in the management plan for medically operable early-stage malignant pleural mesothelioma.
    Shohdy K; Abdel-Rahman O
    Expert Rev Respir Med; 2019 Jun; 13(6):579-584. PubMed ID: 30977408
    [No Abstract]   [Full Text] [Related]  

  • 10. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
    Buikhuisen WA; Burgers JA; Vincent AD; Korse CM; van Klaveren RJ; Schramel FM; Pavlakis N; Nowak AK; Custers FL; Schouwink JH; Gans SJ; Groen HJ; Strankinga WF; Baas P
    Lancet Oncol; 2013 May; 14(6):543-51. PubMed ID: 23583604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of conservative (palliative) care-only in the management of advanced malignant pleural mesothelioma.
    Levy A; Assouline A; Rivera S; Chargari C; Tai P
    Anticancer Res; 2012 Sep; 32(9):4025-7. PubMed ID: 22993354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimum Clinical Recommendations for diagnosis, treatment and follow-up of malignant pleural mesothelioma.
    Manegold C; Stahel RA;
    Ann Oncol; 2005; 16 Suppl 1():i32-3. PubMed ID: 15888745
    [No Abstract]   [Full Text] [Related]  

  • 13. Current trends in the management of malignant pleural mesothelioma.
    Tsiouris A; Gourgoulianis KI; Walesby RK
    Expert Rev Anticancer Ther; 2006 Jun; 6(6):831-3. PubMed ID: 16761925
    [No Abstract]   [Full Text] [Related]  

  • 14. [Surgery for malignant pleural mesothelioma].
    Giudicelli R
    Rev Pneumol Clin; 2004 Apr; 60(2):68-72. PubMed ID: 15133442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
    Ceresoli GL; Aerts JG; Dziadziuszko R; Ramlau R; Cedres S; van Meerbeeck JP; Mencoboni M; Planchard D; Chella A; Crinò L; Krzakowski M; Rüssel J; Maconi A; Gianoncelli L; Grosso F
    Lancet Oncol; 2019 Dec; 20(12):1702-1709. PubMed ID: 31628016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pleurectomy/decortication and hyperthermic intrapleural chemotherapy for malignant pleural mesothelioma: initial experience.
    Migliore M; Calvo D; Criscione A; Palmucci S; Fuccio Sanzà G; Caltabiano R; Spatola C; Privitera G; Aiello MM; Parra HS; Ciancio N; Di Maria G
    Future Oncol; 2015; 11(24 Suppl):19-22. PubMed ID: 26638918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pleurectomy/decortication plus chemotherapy: outcomes of 40 cases of malignant pleural mesothelioma.
    Colaut F; Toniolo L; Vicario G; Scapinello A; Visentin C; Manente P; Sartori CA
    Chir Ital; 2004; 56(6):781-6. PubMed ID: 15771030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Malignant mesothelioma of the pleura: place of surgery].
    Giudicelli R; Regnard JF; Astoul P; Ruffie P
    Rev Mal Respir; 2006 Sep; 23(4 Pt 2):10S106-10S109. PubMed ID: 17127980
    [No Abstract]   [Full Text] [Related]  

  • 19. Mesothelioma clinical presentation.
    Bueno R
    Chest; 1999 Dec; 116(6 Suppl):444S-445S. PubMed ID: 10619504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long progression-free survival by pemetrexed continuation maintenance therapy following cisplatin-based chemotherapy in malignant pleural mesothelioma.
    Takeda T; Itano H; Fukita S; Saitoh M; Takeda S
    Intern Med; 2014; 53(20):2347-51. PubMed ID: 25318801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.